News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rockland Immunochemicals Awarded Phase I SBIR Funding to Develop Generic Antibodies "Biosimilars" for the Treatment of Cancer


10/26/2010 9:02:10 AM

GILBERTSVILLE, Pa.--(BUSINESS WIRE)--Rockland Immunochemicals Inc., (www.rockland-inc.com) a biotechnology company focusing on antibodies and antibody based tools for basic research, diagnostic assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop Generic Antibodies “Biosimilars” for the Treatment of Cancer.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES